Low molecular weight heparins versus rivaroxaban for prevention of lower extremity deep venous thrombosis following surgery of bone metastases
10.3969/j.issn.2095-4344.2014.31.027
- VernacularTitle:低分子肝素与利伐沙班预防骨转移癌术后下肢深静脉血栓的形成
- Author:
Dianwen QI
;
Guochuan ZHANG
;
Wenhai HU
;
Tongyu HU
;
Changzhi GUO
;
Ming ZHAO
;
Zhiwei ZHONG
- Publication Type:Journal Article
- Keywords:
bone neoplasms;
thromboembolism;
venous thrombosis;
heparin
- From:
Chinese Journal of Tissue Engineering Research
2014;(31):5080-5084
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:The risk of lower extremity deep venous thrombosis was high in patients with bone metastases. Major surgery is a major risk factor for thrombosis. There was no standard prophylactic regimen available.
OBJECTIVE:To investigate the efficacy and safety of low molecular weight heparins versus rivaroxaban in the postoperative prevention of lower extremity deep venous thrombosis in patients with bone metastases.
METHODS:From January 2010 to December 2013, a total of 73 patients with bone metastasis in spine, pelvis and lower extremities, who underwent open surgery in the Department of Musculoskeletal Tumor, Third Hospital, Hebei Medical University, China, were retrospectively analyzed. The patients were divided into low molecular weight heparins group (n=41) and rivaroxaban group (n=32) according to the prophylactic drugs after surgery.
RESULTS AND CONCLUSION:Nine cases (22%) in the low molecular weight heparins group were found lower extremity deep venous thrombosis, and six cases (19%) in the rivaroxaban group suffered from lower extremity deep venous thrombosis, showing no significant differences (χ2=0.11, P=0.74). The incidences of bleeding events in both groups were respectively 7.32%and 6.25%, showing no significant differences (correctionχ2=0.083, P>0.05). There were no significant differences regarding the levels of platelet, activated partial thromboplastin time and prothrombin time between both groups preoperatively or postoperatively (P>0.05). Therefore, the efficacy and safety of low molecular weight heparins and rivaroxaban in the postoperative prevention of lower extremity deep venous thrombosis were similar. Both could effectively reduce the incidence of deep venous thrombosis, with a relative low risk of bleeding.
